首页 > 最新文献

Advances in Clinical and Experimental Medicine最新文献

英文 中文
Effect of proton pump inhibitors compared to histamine-2 receptor antagonists on bleeding management and wound healing after endoscopic mucosal resection or endoscopic submucosal dissection: A meta-analysis of randomized clinical trials. 质子泵抑制剂与组胺-2受体拮抗剂相比对内镜粘膜切除术或内镜粘膜下剥离术后出血处理和伤口愈合的影响:随机临床试验荟萃分析。
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-01 DOI: 10.17219/acem/176892
Yishang Wang, Meiling Shu, Bin Yang, Zhili Zhao, Xiaoqi Long

Introduction: Proton pump inhibitors (PPIs) and histamine type-2 receptor antagonists (H2RAs) are generally effective in preventing delayed bleeding and healing artificial wounds after endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD). This study aimed to review the therapeutic effects of PPIs and H2RAs on damage caused by EMR and ESD.

Material and methods: Thirteen articles were collected between 2002 and 2022 by searching Medlib, ScienceDirect, PubMed, International Scientific Indexing (ISI), Embase, and Scopus databases using valid keywords. The main inclusion criteria were delayed wound healing, bleeding, epigastric pain, intraoperative bleeding, and perforation. The odds ratio (OR) and 95% confidence interval (95% CI) were evaluated using a random or fixed effects model. Data analysis was performed using Stata v. 14.2.

Results: A total of 13 articles including 1,483 patients were analyzed. The results showed that delayed bleeding was significantly less frequent in the PPI group than in the H2RA group (OR = 0.6; 95% CI: 0.39-0.92). Subgroup analysis showed that PPI was more effective in preventing delayed bleeding than H2RA for ESD wounds (OR = 0.65; 95% CI: 0.44-1.08). There was no statistically significant difference between both groups regarding the incidence of epigastric pain, intraoperative bleeding, wound healing, and perforation after endoscopic treatments.

Conclusion: The meta-analysis results reveal that PPI is more effective than H2RA in preventing delayed bleeding after endoscopic treatment, particularly in patients treated with ESD. However, there was no significant difference between PPI and H2RA in terms of intraoperative bleeding, epigastric pain, wound healing, and perforation from endoscopic therapy.

导言:质子泵抑制剂(PPIs)和组胺2型受体拮抗剂(H2RAs)在预防内镜粘膜切除术(EMR)或内镜粘膜下剥离术(ESD)后延迟出血和人工伤口愈合方面普遍有效。本研究旨在回顾 PPIs 和 H2RAs 对 EMR 和 ESD 造成的损伤的治疗效果:通过使用有效关键词搜索 Medlib、ScienceDirect、PubMed、International Scientific Indexing (ISI)、Embase 和 Scopus 数据库,收集了 2002 年至 2022 年间的 13 篇文章。主要纳入标准为伤口愈合延迟、出血、上腹痛、术中出血和穿孔。采用随机或固定效应模型评估了几率比(OR)和 95% 置信区间(95% CI)。数据分析使用 Stata v. 14.2:共分析了 13 篇文章,包括 1,483 名患者。结果显示,PPI 组延迟出血的发生率明显低于 H2RA 组(OR = 0.6;95% CI:0.39-0.92)。亚组分析显示,对于 ESD 伤口,PPI 比 H2RA 更能有效预防延迟出血(OR = 0.65;95% CI:0.44-1.08)。在内镜治疗后上腹痛、术中出血、伤口愈合和穿孔的发生率方面,两组间无统计学差异:荟萃分析结果显示,在预防内镜治疗后延迟出血方面,PPI 比 H2RA 更有效,尤其是在接受 ESD 治疗的患者中。然而,就内镜治疗后的术中出血、上腹痛、伤口愈合和穿孔而言,PPI 和 H2RA 之间没有明显差异。
{"title":"Effect of proton pump inhibitors compared to histamine-2 receptor antagonists on bleeding management and wound healing after endoscopic mucosal resection or endoscopic submucosal dissection: A meta-analysis of randomized clinical trials.","authors":"Yishang Wang, Meiling Shu, Bin Yang, Zhili Zhao, Xiaoqi Long","doi":"10.17219/acem/176892","DOIUrl":"10.17219/acem/176892","url":null,"abstract":"<p><strong>Introduction: </strong>Proton pump inhibitors (PPIs) and histamine type-2 receptor antagonists (H2RAs) are generally effective in preventing delayed bleeding and healing artificial wounds after endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD). This study aimed to review the therapeutic effects of PPIs and H2RAs on damage caused by EMR and ESD.</p><p><strong>Material and methods: </strong>Thirteen articles were collected between 2002 and 2022 by searching Medlib, ScienceDirect, PubMed, International Scientific Indexing (ISI), Embase, and Scopus databases using valid keywords. The main inclusion criteria were delayed wound healing, bleeding, epigastric pain, intraoperative bleeding, and perforation. The odds ratio (OR) and 95% confidence interval (95% CI) were evaluated using a random or fixed effects model. Data analysis was performed using Stata v. 14.2.</p><p><strong>Results: </strong>A total of 13 articles including 1,483 patients were analyzed. The results showed that delayed bleeding was significantly less frequent in the PPI group than in the H2RA group (OR = 0.6; 95% CI: 0.39-0.92). Subgroup analysis showed that PPI was more effective in preventing delayed bleeding than H2RA for ESD wounds (OR = 0.65; 95% CI: 0.44-1.08). There was no statistically significant difference between both groups regarding the incidence of epigastric pain, intraoperative bleeding, wound healing, and perforation after endoscopic treatments.</p><p><strong>Conclusion: </strong>The meta-analysis results reveal that PPI is more effective than H2RA in preventing delayed bleeding after endoscopic treatment, particularly in patients treated with ESD. However, there was no significant difference between PPI and H2RA in terms of intraoperative bleeding, epigastric pain, wound healing, and perforation from endoscopic therapy.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1317-1327"},"PeriodicalIF":2.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141449370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dental ceramic damage associated with incorrect laboratory procedures. 与不正确的实验室程序有关的牙科陶瓷损坏。
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-01 DOI: 10.17219/acem/175971
Magdalena Szawioła-Kirejczyk, Karolina Chmura, Wojciech Ryniewicz

Ceramic is a commonly used material in dentistry for reconstructing missing teeth or their tissues due to its biocompatibility, durability and excellent esthetic properties. Despite these advantages, the ceramic restoration damage remains a significant clinical problem. Its causes can be divided into clinical and laboratory factors. The most known include uneven occlusion, improper preparation, trauma, or parafunctions. This study focuses on characterizing less known laboratory causes of ceramic restoration damage. We reviewed the current literature available in the PubMed and Scopus databases. On the basis of 63 selected studies, 3 basic causes of damage were identified: excessive stresses between the framework and ceramic veneering, poor quality of the connection between the facing layer and the substructure, and defects resulting from the nature of the ceramic material such as defects in the ceramic layer, brittleness and lack of flexibility. The stages of the manufacturing process of various permanent ceramic restorations were presented. By controlling these procedures, we can eliminate the errors, resulting in long-term effective functioning of the ceramic restorations.

陶瓷具有生物相容性、耐久性和极佳的美观特性,是牙科中重建缺失牙齿或其组织的常用材料。尽管具有这些优点,但陶瓷修复体的损坏仍然是一个重要的临床问题。其原因可分为临床因素和实验室因素。最常见的原因包括咬合不均匀、准备不当、外伤或功能障碍。本研究的重点是分析较少为人所知的导致陶瓷修复体损坏的实验室原因。我们查阅了 PubMed 和 Scopus 数据库中的现有文献。在所选的 63 项研究的基础上,确定了造成损坏的 3 个基本原因:框架和陶瓷贴面之间的应力过大;面层和下部结构之间的连接质量差;陶瓷材料的性质造成的缺陷,如陶瓷层的缺陷、脆性和缺乏弹性。会上介绍了各种永久性陶瓷修复体生产过程的各个阶段。通过控制这些程序,我们可以消除误差,使陶瓷修复体长期有效地发挥作用。
{"title":"Dental ceramic damage associated with incorrect laboratory procedures.","authors":"Magdalena Szawioła-Kirejczyk, Karolina Chmura, Wojciech Ryniewicz","doi":"10.17219/acem/175971","DOIUrl":"10.17219/acem/175971","url":null,"abstract":"<p><p>Ceramic is a commonly used material in dentistry for reconstructing missing teeth or their tissues due to its biocompatibility, durability and excellent esthetic properties. Despite these advantages, the ceramic restoration damage remains a significant clinical problem. Its causes can be divided into clinical and laboratory factors. The most known include uneven occlusion, improper preparation, trauma, or parafunctions. This study focuses on characterizing less known laboratory causes of ceramic restoration damage. We reviewed the current literature available in the PubMed and Scopus databases. On the basis of 63 selected studies, 3 basic causes of damage were identified: excessive stresses between the framework and ceramic veneering, poor quality of the connection between the facing layer and the substructure, and defects resulting from the nature of the ceramic material such as defects in the ceramic layer, brittleness and lack of flexibility. The stages of the manufacturing process of various permanent ceramic restorations were presented. By controlling these procedures, we can eliminate the errors, resulting in long-term effective functioning of the ceramic restorations.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1409-1419"},"PeriodicalIF":2.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140027167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-amyloid treatments in Alzheimer's disease: elegance, evidence and ethics.
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-01 DOI: 10.17219/acem/198674
Timothy Daly, Andi Olluri, Markku Kurkinen

The so-called "amyloid cascade hypothesis" provides an elegant explanation of Alzheimer's disease (AD), has motivated the amyloid-lowering therapeutic strategy, and led to the elaboration of a rich experimental and conceptual toolkit for the field to progress. But it might be incorrect. The scientific evidence base supporting the efficacy and safety of current anti-amyloid antibody treatments in AD is weak. Nevertheless, we argue that there is a bias towards the amyloid-lowering therapeutic strategy amongst key opinion leaders in the research and advocacy communities. To demonstrate this, we first focus on the AD lexicon: while any accrual of amyloid on a brain PET scan can now permit diagnosis/definition of AD, lowering positron emission tomography (PET) amyloid is considered disease modification, and treatment-induced side-effects are hidden behind neutral-sounding acronyms: ARIA (amyloid-β (Aβ)-related imaging abnormalities: brain bleeding and swelling) and ARPA (amyloid-β (Aβ) removal-related pseudo-atrophy: brain shrinkage). Second, we underline that drugmakers did not test anti-amyloid antibodies against the best proven interventions and did not adequately inform trial participants of risks, thus violating research ethics of the Declaration of Helsinki on 2 counts. In conclusion, we are critical of over-reliance on the idea that PET amyloid-lowering treatments for AD are a therapeutic revolution as claimed, and consider that optimism does not excuse a lack of scientific, regulatory, and ethical integrity. We argue for rigorous, properly controlled (e.g. donepezil) anti-amyloid trials demonstrating cognitive and functional benefit before accepting amyloid-lowering drugs as the new standard of care for AD patients.

{"title":"Anti-amyloid treatments in Alzheimer's disease: elegance, evidence and ethics.","authors":"Timothy Daly, Andi Olluri, Markku Kurkinen","doi":"10.17219/acem/198674","DOIUrl":"10.17219/acem/198674","url":null,"abstract":"<p><p>The so-called \"amyloid cascade hypothesis\" provides an elegant explanation of Alzheimer's disease (AD), has motivated the amyloid-lowering therapeutic strategy, and led to the elaboration of a rich experimental and conceptual toolkit for the field to progress. But it might be incorrect. The scientific evidence base supporting the efficacy and safety of current anti-amyloid antibody treatments in AD is weak. Nevertheless, we argue that there is a bias towards the amyloid-lowering therapeutic strategy amongst key opinion leaders in the research and advocacy communities. To demonstrate this, we first focus on the AD lexicon: while any accrual of amyloid on a brain PET scan can now permit diagnosis/definition of AD, lowering positron emission tomography (PET) amyloid is considered disease modification, and treatment-induced side-effects are hidden behind neutral-sounding acronyms: ARIA (amyloid-β (Aβ)-related imaging abnormalities: brain bleeding and swelling) and ARPA (amyloid-β (Aβ) removal-related pseudo-atrophy: brain shrinkage). Second, we underline that drugmakers did not test anti-amyloid antibodies against the best proven interventions and did not adequately inform trial participants of risks, thus violating research ethics of the Declaration of Helsinki on 2 counts. In conclusion, we are critical of over-reliance on the idea that PET amyloid-lowering treatments for AD are a therapeutic revolution as claimed, and consider that optimism does not excuse a lack of scientific, regulatory, and ethical integrity. We argue for rigorous, properly controlled (e.g. donepezil) anti-amyloid trials demonstrating cognitive and functional benefit before accepting amyloid-lowering drugs as the new standard of care for AD patients.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1303-1309"},"PeriodicalIF":2.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142852072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanisms of resistance to venetoclax in hematologic malignancies. 血液恶性肿瘤患者对 Venetoclax 产生耐药性的机制。
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-01 DOI: 10.17219/acem/181145
Klaudia Zielonka, Krzysztof Jamroziak

Venetoclax, a BH3 mimetic, is a novel targeted anti-cancer drug with a unique mechanism of action leading to the execution of apoptosis through inhibition of the Bcl-2 protein. The development of venetoclax has revolutionized the treatment paradigm of several hematologic malignancies, including treatment-naïve and relapsed or refractory chronic lymphocytic leukemia (CLL) as well as acute myeloid leukemia (AML) in unfit patients. However, despite the high effectiveness of venetoclax in these diseases, some patients, as in the case with other targeted therapies, develop primary or secondary resistance to the drug. Various mechanisms contributing to the resistance to venetoclax have been elucidated, including selection of mutations in the BCL-2 binding groove which decrease affinity to venetoclax, or compensatory overexpression of anti-apoptotic proteins such as MCL-1. Moreover, alterations in cell metabolism and signaling pathways like MAPK or ERK activation have also been reported, suggesting the resistance to venetoclax is highly complex and involves multiple pathways. This review aimed to describe the mechanisms of resistance to venetoclax in AML, CLL, multiple myeloma, and other hematologic malignancies, as well as to propose a perspective to circumvent it.

Venetoclax是一种BH3模拟物,是一种新型靶向抗癌药物,其独特的作用机制可通过抑制Bcl-2蛋白导致细胞凋亡。Venetoclax 的开发彻底改变了多种血液系统恶性肿瘤的治疗模式,包括治疗无效、复发或难治的慢性淋巴细胞白血病(CLL)以及不适患者的急性髓性白血病(AML)。然而,尽管 venetoclax 对这些疾病具有很高的疗效,但与其他靶向疗法一样,一些患者也会产生原发性或继发性耐药性。目前已阐明了导致对 venetoclax 产生耐药性的各种机制,包括 BCL-2 结合沟中发生突变从而降低了对 venetoclax 的亲和力,或 MCL-1 等抗凋亡蛋白的代偿性过度表达。此外,细胞代谢和信号通路(如MAPK或ERK激活)的改变也有报道,这表明对venetoclax的耐药性非常复杂,涉及多种途径。本综述旨在描述AML、CLL、多发性骨髓瘤和其他血液恶性肿瘤对venetoclax的耐药机制,并提出规避耐药的观点。
{"title":"Mechanisms of resistance to venetoclax in hematologic malignancies.","authors":"Klaudia Zielonka, Krzysztof Jamroziak","doi":"10.17219/acem/181145","DOIUrl":"10.17219/acem/181145","url":null,"abstract":"<p><p>Venetoclax, a BH3 mimetic, is a novel targeted anti-cancer drug with a unique mechanism of action leading to the execution of apoptosis through inhibition of the Bcl-2 protein. The development of venetoclax has revolutionized the treatment paradigm of several hematologic malignancies, including treatment-naïve and relapsed or refractory chronic lymphocytic leukemia (CLL) as well as acute myeloid leukemia (AML) in unfit patients. However, despite the high effectiveness of venetoclax in these diseases, some patients, as in the case with other targeted therapies, develop primary or secondary resistance to the drug. Various mechanisms contributing to the resistance to venetoclax have been elucidated, including selection of mutations in the BCL-2 binding groove which decrease affinity to venetoclax, or compensatory overexpression of anti-apoptotic proteins such as MCL-1. Moreover, alterations in cell metabolism and signaling pathways like MAPK or ERK activation have also been reported, suggesting the resistance to venetoclax is highly complex and involves multiple pathways. This review aimed to describe the mechanisms of resistance to venetoclax in AML, CLL, multiple myeloma, and other hematologic malignancies, as well as to propose a perspective to circumvent it.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1421-1433"},"PeriodicalIF":2.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140027168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrated analysis of a competing endogenous RNA network reveals a ferroptosis-related 6-lncRNA prognostic signature in clear cell renal cell carcinoma. 对竞争性内源性 RNA 网络的综合分析揭示了透明细胞肾细胞癌中与铁突变相关的 6-lncRNA 预后特征。
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-01 DOI: 10.17219/acem/176050
Qing Zheng, Zhenqi Gong, Shaoxiong Lin, Dehua Ou, Weilong Lin, Peilin Shen

Background: Establishing a robust signature for prognostic prediction and precision treatment is necessary due to the heterogeneous prognosis and treatment response of clear cell renal cell carcinoma (ccRCC).

Objectives: This study set out to elucidate the biological functions and prognostic role of ferroptosis-related long non-coding RNAs (lncRNAs) based on a synthetic analysis of competing endogenous RNA networks in ccRCC.

Material and methods: Ferroptosis-related genes were obtained from the FerrDb database. The expression data and matched clinical information of lncRNAs, miRNAs and mRNAs from The Cancer Genome Atlas (TCGA) database were obtained to identify differentially expressed RNAs. The lncRNA-miRNA-mRNA ceRNA network was established utilizing the common miRNAs that were predicted in the RNAHybrid, StarBase and TargetScan databases. Then, using progressive univariate Cox regression, least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analysis of gene expression data and clinical information, a ferroptosis-related lncRNA prognosis signature was constructed based on the lncRNAs in ceRNA. Finally, the influence of independent lncRNAs on ccRCC was explored.

Results: A total of 35 ferroptosis-related mRNAs, 356 lncRNAs and 132 miRNAs were sorted out after differential expression analysis in the TCGA-KIRC. Subsequently, overlapping lncRNA-miRNA and miRNA-mRNA interactions among the RNAHybrid, StarBase and TargetScan databases were constructed and identified; then a ceRNA network with 77 axes related to ferroptosis was established utilizing mutual miRNAs in 2 interaction networks as nodes. Next, a 6-ferroptosis-lncRNA signature including PVT1, CYTOR, MIAT, SNHG17, LINC00265, and LINC00894 was identified in the training set. Kaplan-Meier analysis, PCA, t-SNE analysis, risk score curve, and receiver operating characteristic (ROC) curve were performed to confirm the validity of the signature in the training set and verified in the validation set. Finally, single-sample gene set enrichment analysis (ssGSEA) and ESTIMATE (Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data) analysis showed that the signature was related to immune cell infiltration.

Conclusions: Our research underlines the role of the 6-ferroptosis-lncRNA signature as a predictor of prognosis and a therapeutic alternative for ccRCC.

背景:由于透明细胞肾癌(ccRCC)的预后和治疗反应各不相同,因此有必要建立一个用于预后预测和精准治疗的强大特征:由于透明细胞肾细胞癌(ccRCC)的预后和治疗反应各不相同,因此有必要建立一个用于预后预测和精准治疗的强大特征:本研究旨在基于对ccRCC中竞争性内源性RNA网络的合成分析,阐明铁蛋白沉积相关长非编码RNA(lncRNA)的生物学功能和预后作用:从FerrDb数据库中获取铁蛋白沉积相关基因。从癌症基因组图谱(TCGA)数据库中获取lncRNA、miRNA和mRNA的表达数据和匹配的临床信息,以识别差异表达的RNA。利用RNAHybrid、StarBase和TargetScan数据库中预测的常见miRNA,建立了lncRNA-miRNA-mRNA ceRNA网络。然后,利用渐进式单变量 Cox 回归、最小绝对收缩和选择算子(LASSO)以及对基因表达数据和临床信息的多变量 Cox 回归分析,根据 ceRNA 中的 lncRNA 构建了与铁昏迷相关的 lncRNA 预后特征。最后,探讨了独立的lncRNA对ccRCC的影响:结果:在TCGA-KIRC中进行差异表达分析后,共筛选出35个铁变态相关mRNA、356个lncRNA和132个miRNA。随后,构建并鉴定了RNAHybrid、StarBase和TargetScan数据库中重叠的lncRNA-miRNA和miRNA-mRNA之间的相互作用;然后,以2个相互作用网络中的相互miRNA为节点,建立了一个与铁变态反应相关的、包含77个轴的ceRNA网络。然后,在训练集中确定了包括 PVT1、CYTOR、MIAT、SNHG17、LINC00265 和 LINC00894 在内的 6 个铁变态反应-lncRNA 特征。通过卡普兰-梅耶分析、PCA、t-SNE 分析、风险评分曲线和接收者操作特征曲线(ROC),确认了训练集中特征的有效性,并在验证集中进行了验证。最后,单样本基因组富集分析(ssGSEA)和ESTIMATE(利用表达数据估算恶性肿瘤组织中的基质细胞和免疫细胞)分析表明,该特征与免疫细胞浸润有关:我们的研究强调了 6-ferroptosis-lncRNA 特征作为 ccRCC 预后预测指标和治疗选择的作用。
{"title":"Integrated analysis of a competing endogenous RNA network reveals a ferroptosis-related 6-lncRNA prognostic signature in clear cell renal cell carcinoma.","authors":"Qing Zheng, Zhenqi Gong, Shaoxiong Lin, Dehua Ou, Weilong Lin, Peilin Shen","doi":"10.17219/acem/176050","DOIUrl":"10.17219/acem/176050","url":null,"abstract":"<p><strong>Background: </strong>Establishing a robust signature for prognostic prediction and precision treatment is necessary due to the heterogeneous prognosis and treatment response of clear cell renal cell carcinoma (ccRCC).</p><p><strong>Objectives: </strong>This study set out to elucidate the biological functions and prognostic role of ferroptosis-related long non-coding RNAs (lncRNAs) based on a synthetic analysis of competing endogenous RNA networks in ccRCC.</p><p><strong>Material and methods: </strong>Ferroptosis-related genes were obtained from the FerrDb database. The expression data and matched clinical information of lncRNAs, miRNAs and mRNAs from The Cancer Genome Atlas (TCGA) database were obtained to identify differentially expressed RNAs. The lncRNA-miRNA-mRNA ceRNA network was established utilizing the common miRNAs that were predicted in the RNAHybrid, StarBase and TargetScan databases. Then, using progressive univariate Cox regression, least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analysis of gene expression data and clinical information, a ferroptosis-related lncRNA prognosis signature was constructed based on the lncRNAs in ceRNA. Finally, the influence of independent lncRNAs on ccRCC was explored.</p><p><strong>Results: </strong>A total of 35 ferroptosis-related mRNAs, 356 lncRNAs and 132 miRNAs were sorted out after differential expression analysis in the TCGA-KIRC. Subsequently, overlapping lncRNA-miRNA and miRNA-mRNA interactions among the RNAHybrid, StarBase and TargetScan databases were constructed and identified; then a ceRNA network with 77 axes related to ferroptosis was established utilizing mutual miRNAs in 2 interaction networks as nodes. Next, a 6-ferroptosis-lncRNA signature including PVT1, CYTOR, MIAT, SNHG17, LINC00265, and LINC00894 was identified in the training set. Kaplan-Meier analysis, PCA, t-SNE analysis, risk score curve, and receiver operating characteristic (ROC) curve were performed to confirm the validity of the signature in the training set and verified in the validation set. Finally, single-sample gene set enrichment analysis (ssGSEA) and ESTIMATE (Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data) analysis showed that the signature was related to immune cell infiltration.</p><p><strong>Conclusions: </strong>Our research underlines the role of the 6-ferroptosis-lncRNA signature as a predictor of prognosis and a therapeutic alternative for ccRCC.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1391-1407"},"PeriodicalIF":2.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140100769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mesoderm/mesenchyme homeobox l may promote tumor progression in human hepatocellular carcinoma. 中胚层/间充质同源染色体l可能会促进人类肝细胞癌的肿瘤进展。
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-01 DOI: 10.17219/acem/175819
Jie Ruan, Ying Xie, Huifang Zhou, Chao Liu, Dianxing Sun

Background: The clinical response rate for molecularly targeted medications is limited despite significant advancements in molecularly targeted therapy for hepatocellular carcinoma (HCC). Therefore, it is necessary to find new and robust therapeutic targets for the treatment of HCC. Recent research has shown that mesoderm/mesenchyme homeobox gene 1 (Meox1) is closely associated with cancer progression.

Objectives: The aim of this study was to evaluate the clinical relevance as well as biological function of Meox1 in HCC.

Material and methods: Meox1 protein expression level was identified through immunohistochemistry (IHC) examination of pathological tissues from 25 HCC patients. The aim of the analysis was to investigate the relationship between clinicopathological traits and Meox1 expression. Biological function assays of Meox1 in HCC, including proliferation, colony formation, migration, and invasion, were performed with Huh7 and Hep3B cells.

Results: In this study, Meox1 expression in HCC tissues was significantly higher (p < 0.05) compared to paracancerous tissues. Especially in HCC tissues of patients with cirrhosis, the level of Meox1 expression was significantly elevated when compared to HCC tissues of patients without cirrhosis (p < 0.05). High Meox1 expression was significantly associated with tumor-node-metastasis (TNM) stage (p < 0.05) and the Barcelona Clinic Liver Cancer (BCLC) stage (p < 0.05). Moreover, Meox1 silencing suppressed the proliferation, colony formation, migration, and invasion of Huh7 and Hep3B cells.

Conclusions: Our data reveal that Meox1 may play a crucial role in the development of HCC, and given the function of Meox1 in proliferation and metastasis, targeting Meox1 may offer a promising approach for combined and adjuvant therapeutics of HCC.

背景:尽管肝细胞癌(HCC)的分子靶向治疗取得了重大进展,但分子靶向药物的临床反应率有限。因此,有必要为治疗 HCC 寻找新的、强有力的治疗靶点。最近的研究表明,中胚层/间充质同源框基因 1(Meox1)与癌症进展密切相关:本研究旨在评估 Meox1 在 HCC 中的临床相关性和生物学功能:通过对 25 例 HCC 患者的病理组织进行免疫组化(IHC)检查,确定 Meox1 蛋白的表达水平。分析的目的是研究临床病理特征与 Meox1 表达之间的关系。用Huh7和Hep3B细胞进行了Meox1在HCC中的生物功能测试,包括增殖、集落形成、迁移和侵袭:结果:与癌旁组织相比,Meox1在HCC组织中的表达明显升高(P < 0.05)。特别是在肝硬化患者的 HCC 组织中,与非肝硬化患者的 HCC 组织相比,Meox1 的表达水平明显升高(p < 0.05)。Meox1的高表达与肿瘤-结节-转移(TNM)分期(p < 0.05)和巴塞罗那临床肝癌(BCLC)分期(p < 0.05)明显相关。此外,Meox1沉默抑制了Huh7和Hep3B细胞的增殖、集落形成、迁移和侵袭:我们的数据揭示了Meox1可能在HCC的发展中起着至关重要的作用,鉴于Meox1在增殖和转移中的功能,靶向Meox1可能为HCC的联合和辅助治疗提供了一种有前景的方法。
{"title":"Mesoderm/mesenchyme homeobox l may promote tumor progression in human hepatocellular carcinoma.","authors":"Jie Ruan, Ying Xie, Huifang Zhou, Chao Liu, Dianxing Sun","doi":"10.17219/acem/175819","DOIUrl":"10.17219/acem/175819","url":null,"abstract":"<p><strong>Background: </strong>The clinical response rate for molecularly targeted medications is limited despite significant advancements in molecularly targeted therapy for hepatocellular carcinoma (HCC). Therefore, it is necessary to find new and robust therapeutic targets for the treatment of HCC. Recent research has shown that mesoderm/mesenchyme homeobox gene 1 (Meox1) is closely associated with cancer progression.</p><p><strong>Objectives: </strong>The aim of this study was to evaluate the clinical relevance as well as biological function of Meox1 in HCC.</p><p><strong>Material and methods: </strong>Meox1 protein expression level was identified through immunohistochemistry (IHC) examination of pathological tissues from 25 HCC patients. The aim of the analysis was to investigate the relationship between clinicopathological traits and Meox1 expression. Biological function assays of Meox1 in HCC, including proliferation, colony formation, migration, and invasion, were performed with Huh7 and Hep3B cells.</p><p><strong>Results: </strong>In this study, Meox1 expression in HCC tissues was significantly higher (p < 0.05) compared to paracancerous tissues. Especially in HCC tissues of patients with cirrhosis, the level of Meox1 expression was significantly elevated when compared to HCC tissues of patients without cirrhosis (p < 0.05). High Meox1 expression was significantly associated with tumor-node-metastasis (TNM) stage (p < 0.05) and the Barcelona Clinic Liver Cancer (BCLC) stage (p < 0.05). Moreover, Meox1 silencing suppressed the proliferation, colony formation, migration, and invasion of Huh7 and Hep3B cells.</p><p><strong>Conclusions: </strong>Our data reveal that Meox1 may play a crucial role in the development of HCC, and given the function of Meox1 in proliferation and metastasis, targeting Meox1 may offer a promising approach for combined and adjuvant therapeutics of HCC.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1379-1389"},"PeriodicalIF":2.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139721188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What do we know about eligible organ donors? Analysis of data from a local Registry. 我们对符合条件的器官捐献者了解多少?对地方登记处数据的分析。
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-01 DOI: 10.17219/acem/182940
Michał Kisiołek, Bartosz Blada, Jędrzej Hyla, Jakub Sikora, Zbigniew Putowski, Łukasz Krzych, Wojciech Saucha

Background: The imbalance between supply and demand for organ donations remains a hot topic for international debate. Brain-dead organ donors (DBDs) constitute the majority of organ donations in Poland.

Objectives: To identify the factors that guided intensivists in qualifying a brain-dead patient as a potential organ donor, and whether the factors that significantly influenced the decision to qualify constituted an actual contraindication.

Material and methods: We performed a retrospective study based on data from the Silesian ICU Registry from 2010-2020 and publicly available information from Poltransplant. We compared the demographic and clinical characteristics of patients diagnosed with brain death who were identified as eligible and ineligible organ donors.

Results: Out of 25,465 patients enrolled in the Silesian ICU Registry, brain death was diagnosed in 385 (1.51%) study participants, and 61 of the records were excluded due to data incompleteness. In the remaining group (n = 324), there were 201 men and 123 women. Of them, only 180 study participants were reported as eligible donors (55.5%). Six patients had absolute contraindications to organ donation.

Conclusions: A relatively small number of patients diagnosed with brain death were qualified by intensivists as eligible organ donors, with a limited number of medical factors influencing this decision. This means that other non-medical factors may affect the qualification of DBDs for organ procurement.

背景:器官捐献供需失衡仍是国际辩论的热门话题。在波兰,脑死亡器官捐献者(DBD)占器官捐献的大多数:目的:确定引导重症监护医师将脑死亡患者鉴定为潜在器官捐献者的因素,以及对鉴定决定有重大影响的因素是否构成实际禁忌症:我们根据 2010-2020 年西里西亚重症监护室登记处的数据和 Poltransplant 的公开信息进行了一项回顾性研究。我们比较了被确诊为符合和不符合器官捐献条件的脑死亡患者的人口统计学和临床特征:在西里西亚重症监护室登记处登记的 25465 名患者中,有 385 人(1.51%)被诊断为脑死亡,其中 61 份记录因数据不完整而被排除。剩下的一组(n = 324)中有 201 名男性和 123 名女性。其中,只有 180 名研究参与者符合捐献条件(55.5%)。6名患者有器官捐献的绝对禁忌症:结论:相对较少的脑死亡患者被重症监护医生认定为符合器官捐献条件,影响这一决定的医学因素有限。这意味着其他非医疗因素可能会影响脑死亡患者的器官获取资格。
{"title":"What do we know about eligible organ donors? Analysis of data from a local Registry.","authors":"Michał Kisiołek, Bartosz Blada, Jędrzej Hyla, Jakub Sikora, Zbigniew Putowski, Łukasz Krzych, Wojciech Saucha","doi":"10.17219/acem/182940","DOIUrl":"10.17219/acem/182940","url":null,"abstract":"<p><strong>Background: </strong>The imbalance between supply and demand for organ donations remains a hot topic for international debate. Brain-dead organ donors (DBDs) constitute the majority of organ donations in Poland.</p><p><strong>Objectives: </strong>To identify the factors that guided intensivists in qualifying a brain-dead patient as a potential organ donor, and whether the factors that significantly influenced the decision to qualify constituted an actual contraindication.</p><p><strong>Material and methods: </strong>We performed a retrospective study based on data from the Silesian ICU Registry from 2010-2020 and publicly available information from Poltransplant. We compared the demographic and clinical characteristics of patients diagnosed with brain death who were identified as eligible and ineligible organ donors.</p><p><strong>Results: </strong>Out of 25,465 patients enrolled in the Silesian ICU Registry, brain death was diagnosed in 385 (1.51%) study participants, and 61 of the records were excluded due to data incompleteness. In the remaining group (n = 324), there were 201 men and 123 women. Of them, only 180 study participants were reported as eligible donors (55.5%). Six patients had absolute contraindications to organ donation.</p><p><strong>Conclusions: </strong>A relatively small number of patients diagnosed with brain death were qualified by intensivists as eligible organ donors, with a limited number of medical factors influencing this decision. This means that other non-medical factors may affect the qualification of DBDs for organ procurement.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1349-1355"},"PeriodicalIF":2.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139728765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond the boundaries: Transitioning from categorical to dimensional paradigms in mental health diagnostics.
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-01 DOI: 10.17219/acem/197425
Masaru Tanaka

Mental health diagnostics is undergoing a transformation, with a shift away from traditional categorical systems like the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), and the International Classification of Diseases, 11th Revision (ICD-11), and toward innovative frameworks like the Hierarchical Taxonomy of Psychopathology (HiTOP) and the Research Domain Criteria (RDoC). These emerging models prioritize dimensional and biobehavioral approaches in order to overcome limitations such as oversimplification, comorbidity and heterogeneity. This editorial explores the challenges of implementing these paradigms, such as the need for empirical validation, interdisciplinary collaboration and clinician training. It highlights the importance of advanced tools, biomarkers and technological integration to improve precision in diagnosis and treatment. Future research directions include creating reliable dimensional assessment methods, conducting longitudinal studies and fostering interdisciplinary networks. By bridging traditional and emerging frameworks, the field can progress toward personalized, biologically informed mental health treatment. This transition necessitates collaboration among researchers, clinicians and policymakers to improve diagnostic accuracy and treatment outcomes for those affected by mental health disorders.

{"title":"Beyond the boundaries: Transitioning from categorical to dimensional paradigms in mental health diagnostics.","authors":"Masaru Tanaka","doi":"10.17219/acem/197425","DOIUrl":"10.17219/acem/197425","url":null,"abstract":"<p><p>Mental health diagnostics is undergoing a transformation, with a shift away from traditional categorical systems like the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), and the International Classification of Diseases, 11th Revision (ICD-11), and toward innovative frameworks like the Hierarchical Taxonomy of Psychopathology (HiTOP) and the Research Domain Criteria (RDoC). These emerging models prioritize dimensional and biobehavioral approaches in order to overcome limitations such as oversimplification, comorbidity and heterogeneity. This editorial explores the challenges of implementing these paradigms, such as the need for empirical validation, interdisciplinary collaboration and clinician training. It highlights the importance of advanced tools, biomarkers and technological integration to improve precision in diagnosis and treatment. Future research directions include creating reliable dimensional assessment methods, conducting longitudinal studies and fostering interdisciplinary networks. By bridging traditional and emerging frameworks, the field can progress toward personalized, biologically informed mental health treatment. This transition necessitates collaboration among researchers, clinicians and policymakers to improve diagnostic accuracy and treatment outcomes for those affected by mental health disorders.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1295-1301"},"PeriodicalIF":2.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blindness of intentions and metacognitive deficits during moral judgements in schizophrenia. 精神分裂症患者在道德判断过程中的意向盲和元认知缺陷。
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-01 DOI: 10.17219/acem/175918
Tomasz Cyrkot, David Ramsey, Monika Wójta-Kempa, Błażej Misiak, Remigiusz Szczepanowski

Background: Previous research has shown that moral judgments are affected by social cognitive abilities, such as theory of mind (ToM). This study examines how information about an actor's beliefs and the consequences of their actions affect the moral evaluation of the character's behavior in social events. Our research builds upon previous studies, which have shown that these factors contribute differently to moral judgments made by both adults and young children.

Objectives: This study aimed to explore how participants with schizophrenia and healthy controls read stories about social situations in the context of moral judgments.

Material and methods: The study used the research procedure that included 4 variants of 16 scenarios describing social situations, and thus comprising 64 stories. After each story, participants evaluated their confidence level on a 4-point scale. To assess delusional beliefs, the Polish adaptation of the Peters Delusion Inventory (PDI) questionnaire and the Paranoia Checklist (PCh) were used. Respondents completed these questionnaires after completing the scenario test procedure.

Results: In social situations, patients with paranoid schizophrenia were found to evaluate actions of protagonists who attempted to harm another person more leniently than when it was an accident. Conversely, healthy individuals judged those actors who expressed intentions to hurt another person significantly more harshly than in an accident situation. Metacognition measures show that paranoid schizophrenia patients make moral judgments with high confidence, despite being based on an incorrect reading of the other person's intentions.

Conclusions: The study indicates that ToM has a significant impact on the moral judgment of others. Decreased moral cognition can result from both positive and negative symptoms. Deficits related to metacognition can also sustain such cognitive distortions.

研究背景以往的研究表明,道德判断会受到社会认知能力(如心智理论(ToM))的影响。本研究探讨了有关行为者的信念及其行为后果的信息如何影响对社会事件中人物行为的道德评价。我们的研究建立在以往研究的基础之上,这些研究表明,这些因素对成人和幼儿的道德判断有着不同的影响:本研究旨在探讨精神分裂症患者和健康对照者如何在道德判断的背景下阅读有关社会情境的故事:本研究采用的研究程序包括 4 个变体、16 个描述社会情境的情景,共 64 个故事。每个故事结束后,受试者用 4 点量表评估自己的信心水平。为了评估妄想信念,我们使用了波兰语改编的彼得斯妄想量表(PDI)问卷和妄想症核对表(PCh)。受访者在完成情景测试程序后填写这些问卷:结果:研究发现,在社交情境中,偏执型精神分裂症患者对试图伤害他人的主角的行为的评价比对意外事件的评价更为宽松。相反,健康人对那些表达了伤害他人意图的行为者的评价要比意外情况下严厉得多。元认知测量结果显示,偏执型精神分裂症患者做出道德判断时信心十足,尽管他们是基于对他人意图的错误解读:研究表明,道德认知对他人的道德判断有重大影响。积极和消极症状都可能导致道德认知能力下降。与元认知有关的缺陷也会导致这种认知扭曲。
{"title":"Blindness of intentions and metacognitive deficits during moral judgements in schizophrenia.","authors":"Tomasz Cyrkot, David Ramsey, Monika Wójta-Kempa, Błażej Misiak, Remigiusz Szczepanowski","doi":"10.17219/acem/175918","DOIUrl":"10.17219/acem/175918","url":null,"abstract":"<p><strong>Background: </strong>Previous research has shown that moral judgments are affected by social cognitive abilities, such as theory of mind (ToM). This study examines how information about an actor's beliefs and the consequences of their actions affect the moral evaluation of the character's behavior in social events. Our research builds upon previous studies, which have shown that these factors contribute differently to moral judgments made by both adults and young children.</p><p><strong>Objectives: </strong>This study aimed to explore how participants with schizophrenia and healthy controls read stories about social situations in the context of moral judgments.</p><p><strong>Material and methods: </strong>The study used the research procedure that included 4 variants of 16 scenarios describing social situations, and thus comprising 64 stories. After each story, participants evaluated their confidence level on a 4-point scale. To assess delusional beliefs, the Polish adaptation of the Peters Delusion Inventory (PDI) questionnaire and the Paranoia Checklist (PCh) were used. Respondents completed these questionnaires after completing the scenario test procedure.</p><p><strong>Results: </strong>In social situations, patients with paranoid schizophrenia were found to evaluate actions of protagonists who attempted to harm another person more leniently than when it was an accident. Conversely, healthy individuals judged those actors who expressed intentions to hurt another person significantly more harshly than in an accident situation. Metacognition measures show that paranoid schizophrenia patients make moral judgments with high confidence, despite being based on an incorrect reading of the other person's intentions.</p><p><strong>Conclusions: </strong>The study indicates that ToM has a significant impact on the moral judgment of others. Decreased moral cognition can result from both positive and negative symptoms. Deficits related to metacognition can also sustain such cognitive distortions.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1357-1366"},"PeriodicalIF":2.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Limited utility of salivary mineral content in prediction of fragility fractures among postmenopausal women. 唾液矿物质含量对绝经后妇女脆性骨折的预测作用有限。
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-01 DOI: 10.17219/acem/181178
Elżbieta Tabor, Hanna Hüpsch, Joanna Rokicka, Teresa Sierpińska, Jerzy Konstantynowicz, Karolina Orywal, Wojciech Pluskiewicz

Background: Osteoporosis is a metabolic disease characterized by increased bone fragility. As it is characterized as a general skeletal disease, changes can also be seen in the stomatognathic system (edentulism, wrong fitting of dentures, etc.). The question is whether early changes in the salivary mineral content and acid-base balance may reflect skeletal status and risk of bone fracture.

Objectives: The objective of the study was to evaluate whether minerals in the saliva were associated with skeletal fractures in a population of postmenopausal women.

Material and methods: In this observational study, dental examinations along with the collection of saliva were conducted in 117 randomly recruited women (mean age 64.6 ±5.9 years). The study group included 23 study participants with fractures, of which 10 had a history of osteoporotic fractures. Saliva samples for mineral content including copper (Cu), zinc (Zn), calcium (Ca), and phosphorus (P), as well as salivary pH were collected and analyzed to determine associations between salivary mineral content and fracture risk.

Results: As a result, the median pH value was 6.8, and the median levels for Cu (0.35 μmol/L), Zn (0.61 μmol/L), Ca (0.7 mmol/L), and P (6.64 mmol/L) were observed. No differences were noted in salivary mineral content and acid-basic balance between the fractured and non-fractured participants.

Conclusions: The results of our study suggest that salivary mineral content has limited usability in predicting skeletal fragility in postmenopausal women when used alone.

背景:骨质疏松症是一种以骨脆性增加为特征的代谢性疾病。由于骨质疏松症是一种全身性骨骼疾病,因此口颌系统也会发生变化(牙齿松动症、假牙安装错误等)。问题是唾液矿物质含量和酸碱平衡的早期变化是否能反映骨骼状况和骨折风险:本研究的目的是评估唾液中的矿物质是否与绝经后妇女群体中的骨骼骨折有关:在这项观察性研究中,对随机招募的 117 名妇女(平均年龄为 64.6 ± 5.9 岁)进行了牙科检查和唾液采集。研究组包括 23 名骨折患者,其中 10 人有骨质疏松性骨折病史。研究人员收集并分析了唾液样本中的矿物质含量(包括铜(Cu)、锌(Zn)、钙(Ca)和磷(P))以及唾液 pH 值,以确定唾液矿物质含量与骨折风险之间的关联:结果发现,pH 值的中位数为 6.8,铜(0.35 μmol/L)、锌(0.61 μmol/L)、钙(0.7 mmol/L)和磷(6.64 mmol/L)的中位数水平均为 6.64 mmol/L。在唾液矿物质含量和酸碱平衡方面,骨折和非骨折参与者之间没有差异:我们的研究结果表明,单独使用唾液矿物质含量来预测绝经后妇女骨骼脆性的实用性有限。
{"title":"Limited utility of salivary mineral content in prediction of fragility fractures among postmenopausal women.","authors":"Elżbieta Tabor, Hanna Hüpsch, Joanna Rokicka, Teresa Sierpińska, Jerzy Konstantynowicz, Karolina Orywal, Wojciech Pluskiewicz","doi":"10.17219/acem/181178","DOIUrl":"10.17219/acem/181178","url":null,"abstract":"<p><strong>Background: </strong>Osteoporosis is a metabolic disease characterized by increased bone fragility. As it is characterized as a general skeletal disease, changes can also be seen in the stomatognathic system (edentulism, wrong fitting of dentures, etc.). The question is whether early changes in the salivary mineral content and acid-base balance may reflect skeletal status and risk of bone fracture.</p><p><strong>Objectives: </strong>The objective of the study was to evaluate whether minerals in the saliva were associated with skeletal fractures in a population of postmenopausal women.</p><p><strong>Material and methods: </strong>In this observational study, dental examinations along with the collection of saliva were conducted in 117 randomly recruited women (mean age 64.6 ±5.9 years). The study group included 23 study participants with fractures, of which 10 had a history of osteoporotic fractures. Saliva samples for mineral content including copper (Cu), zinc (Zn), calcium (Ca), and phosphorus (P), as well as salivary pH were collected and analyzed to determine associations between salivary mineral content and fracture risk.</p><p><strong>Results: </strong>As a result, the median pH value was 6.8, and the median levels for Cu (0.35 μmol/L), Zn (0.61 μmol/L), Ca (0.7 mmol/L), and P (6.64 mmol/L) were observed. No differences were noted in salivary mineral content and acid-basic balance between the fractured and non-fractured participants.</p><p><strong>Conclusions: </strong>The results of our study suggest that salivary mineral content has limited usability in predicting skeletal fragility in postmenopausal women when used alone.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1343-1348"},"PeriodicalIF":2.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139970583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Advances in Clinical and Experimental Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1